Planning your 2025 weight loss journey? Depending on your plan, FSA and/or HSA funds may be eligible to use with prescription weight loss medications. If not, you still have flexible ways to manage costs. Whether you’re considering … Read more
In today’s business world, healthy employees are a key driver of company success. As more employers recognize this, the demand for effective corporate wellness programs continues to rise. Ivím Health is leading the charge with its innovative … Read more
For those considering Wegovy® (semaglutide), Ozempic® (semaglutide), or compounded semaglutide for weight loss or as a treatment option for type 2 diabetes management, gaining clarity on the financial implications is important. This overview examines costs with insurance … Read more
If you’re experiencing fatigue while taking Ozempic® (semaglutide), Wegovy®(semaglutide), or compounded semaglutide, you’re not alone. Learn how to manage this common side effect and maintain your energy levels. Fortunately, this fatigue is often temporary and manageable with … Read more
FDA notice on Zepbound™/Mounjaro® shortage: On December 19th, 2024, the U.S. Food and Drug Administration determined that the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has ended. Patients may continue receiving essential copies through … Read more
FDA notice on Zepbound™/Mounjaro® shortage: On December 19th, 2024, the U.S. Food and Drug Administration determined that the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has ended. Patients may continue receiving essential copies through … Read more
At Ivím Health, our mission is to deliver unparalleled, personalized care that goes far beyond basic healthcare—and our membership model allows us to do just that. We’re proud to offer so much more than just weight loss … Read more
FDA notice on Zepbound®/Mounjaro® shortage: On October 2, 2024, the U.S. Food and Drug Administration determined that the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, had ended. (Read more) Schedule a visit with an Ivim … Read more
The path to weight loss can often feel daunting, but a new medication called semaglutide is offering fresh optimism. Better known by brand names like Wegovy® and Ozempic®, semaglutide has demonstrated remarkable effectiveness in supporting weight management … Read more
FDA notice on Zepbound®/Mounjaro® shortage: On October 2, 2024, the U.S. Food and Drug Administration determined that the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, had ended. (Read more) Schedule a visit with an Ivim … Read more
